TBPMF News and Press, Tetra Bio-Pharma Inc From 12/16/19

OTTAWA, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the signing of a definitive agreement with Azevedos Ind...

Orphan Drug Designation qualifies Tetra for certain incentives and benefits, including a 50% tax credit upon approval                  Tetra to pursue 505(b)(2) NDA pathway and expedited review for its Orphan Drug candidate HCC...

During the past trading week (December 2 to 6), a cannabinoid-based drug manufacturer in Canada obtained critical status for one of its candidates in the US. An executive at a Canadian marijuana producer was forced to address the volatility surrounding his company after a new acquisition was...

Shares of a Canadian small market cap medical cannabis research firm jumped after it obtained a critical notice from the US Food and Drug Administration (FDA). Tetra Bio-Pharma (TSXV: TBP ,OTCQB:TBPMF) confirmed on Wednesday (December 4) that its delta-9-tetrahydrocannabinol (THC) treatmen...

Tetra to launch Phase 2 trial for treatment of hepatocellular carcinoma in Q1 2020                 Tetra leverages Caumz™ -kit technology to provide a new drug for cancer treatment OTTAWA, Dec. 04, 2019 (GLOBE NEWSWIRE) -...

Alternavida to launch and fund 2 clinical sites in Mexico as part of the clinical research collaboration in the commercialization agreement              Collaboration potentially allows Tetra to accelerate Phase 3 (Serenity) and Phase 2 (fibr...

During the past trading week (November 25 to 29), the two co-owners of a marijuana producer in Canada have officially entered a dispute over the ownership status of the entity. A California-based multi-state operator is pulling back its expansion plans across key states, while NBA superstar ...

OTTAWA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (“TNH”) a wholly   owned subsidiary of Tetra Bio-Pharma Inc ., (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF) today announced that it has submitted two over-the-counter (...

A medical research cannabis company has obtained a critical approval for its investigation of a drug to treat uncontrolled pain in advanced cancer patients. On Monday (November 25), Tetra Bio-Pharma (TSXV: TBP ,OTCQB:TBPMF) informed its shareholders the US Food and Drug Administration (FDA...

Company to resume clinical trial in advanced cancer patients with uncontrolled pain Tetra engages leading clinical collaborator to run Plenitude trial in the U.S. OTTAWA, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma   Inc., (TSX-V: TBP) (OTCQB: TBPMF),  a leader in...